Drug Delivery Technologies: Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies | Life Science Conferences and Market Research Reports

New Report Assesses Impact and Future of Drug Repositioning in the Pharma Industry - read more -

New Reports & Conferences eNewsletter

Drug Delivery Technologies: Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies

Publication Date: September 2008
Pages: 283

Purchasing Info
$3500 (single user)
$6500 (department)
$8500 (global)

BUY THIS REPORT NOW | TABLE OF CONTENTS

The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products. Drug delivery companies not only stand to benefit from patent expiry by providing their reformulation services to pharmaceutical companies, but also by producing their own versions of branded products with improved delivery mechanisms. Thus, post-patent expiry sales can be switched from the ethical manufacturer to the drug delivery sector.

Drug Delivery Technologies: Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies is an up-to-date guide that assesses the current state of the drug delivery industry and its application to both the pharmaceutical and biotech industries. While the sector is still dominated by oral technologies, drug delivery systems have expanded to include more novel devices such as needleless injectables, PEGylation platforms and microelectromechanical devices. These technological advances extend the duration of a drug’s action, increase delivery to target sites, reduce delivery to unwanted sites, and maximize drug absorption.

The expanding market for biotechnology and gene-based products, which by their very nature are difficult to administer, represents an emerging opportunity for drug delivery technologies. These technologies are first expected to come to market as reformulations of existing macromolecular therapies, such as insulin. This report analyzes the markets for oral, inhalable, injectable, transmucosal, transdermal and niche drug delivery technologies as they apply to both biotech and traditional pharmacological compounds.

Key Features of This Report

A thorough overview of both marketed and emerging drug delivery technologies set to impact the global pharmaceutical market
Analysis of the opportunities and threats to the global drug delivery industry
Profiles of drug delivery companies along with key financial figures and technology/product portfolios
Market analysis and outlook for the leading drug delivery technologies, including oral, injectable, inhalable, transdermal, transmucosal and niche technologies
Profiles of key emerging drug delivery technologies and profiles of leading companies, by type of technology
An overview of the global drug delivery market, with sales for key drug delivery categories and key products within each one of the them
Identification of key areas associated with the successful development of new drug delivery systems
Critical assessment of market trends, forecasts and problems in the global drug delivery market
Explanations of key technologies and mechanism of action of new drug delivery technologies and products utilizing them
Thorough descriptions of important areas of research and development in the drug delivery market

What questions does this report answer?

What are the key trends in the field of drug delivery as a whole?
What are the major issues involved in the research and development of more effective drug delivery systems?
What types of drug delivery technologies are currently in research and development in each of the main drug delivery categories?
What is the value of new drug delivery technologies in terms of a product’s lifecycle management?
Which new drug delivery systems are likely to provide the best commercial opportunities for their manufacturers?

Highlights of this report

Discussion and analysis of the problems associated with the use of traditional drug delivery technologies: lack of patient compliance, considerable adverse effects, inferior clinical efficacy due to the lack of targeted delivery
Identification of the challenges to the development of better, more efficacious drug delivery technologies, with fewer side effects
Focused analysis of the global market for major drug delivery technologies: oral, inhalable, injectable, transdermal, transmucosal and topical, as well as niche technologies, such as gene delivery
Identification of the major products in research and development utilizing new technologies
Highlights of the drug delivery systems that are most likely to impact the global market

Reasons to purchase

Provides a comprehensive description of the current state of affairs in the global drug delivery field
Provides a comprehensive description of the main drug delivery technologies and key products within each of the categories
Asesses key products and technologies in clinical development
Provides a guide to optimizing drug reformulation processes
Provides a guide to business models of drug delivery companies
Identifies key issues facing drug delivery and pharmaceutical companies in the development of new drug delivery systems

1 INTRODUCING THE FIELD OF DRUG DELIVERY 15
1.1 THE VALUE OF DRUG DELIVERY SYSTEMS 15
1.2 DRUG DELIVERY AND PRODUCT DIFFERENTIATION 16
1.3 DRUG DELIVERY AND PATENT EXTENSION 17
1.4 THE OPTIMAL TIME FOR REFORMULATION 19
1.5 OPTIMIZING R&D RETURNS THROUGH DRUG DELIVERY 20
1.6 OPPORTUNITIES AND THREATS TO THE DRUG DELIVERY SECTOR 20
1.6.1 Opportunities for Growth in the Drug Delivery Sector 21
1.6.2 Threats to Additional Growth in the Drug Delivery Sector 24
1.7 BUSINESS MODELS OF DRUG DELIVERY COMPANIES 26

2 AN OVERVIEW OF DRUG DELIVERY TECHNOLOGIES 28
2.1 ORAL DRUG DELIVERY 28
2.1.1 Controlled Release 29
2.1.2 Sustained Release 31
2.1.3 Chronomodulation 31
2.1.4 Rapid Dissolving and Taste-masking Tablets 31
2.1.5 Macromolecular Drug Delivery 33
2.1.6 Microemulsion 33
2.1.7 Pulsatile Drug Delivery 34
2.2 INHALABLE DRUG DELIVERY 35
2.2.1 Nebulizers 36
2.2.2 Metered Dose Inhalers (MDIs) 36
2.2.3 Dry Powder Inhalers (DPIs) 37
2.2.4 Limitations of Pulmonary Delivery Systems for Systemic Delivery 38
2.2.5 Aqueous Systems 39
2.2.6 Crystallization Technology 39
2.2.7 Electrohydrodynamic (EHD) Aerosol Delivery 40
2.2.8 Liposomal Systems 40
2.3 INJECTABLE DRUG DELIVERY 41
2.3.1 Sustained Release Injectable Systems 42
2.3.2 Liposomal Systems 43
2.3.3 Needleless Systems 43
2.3.4 New Injectable Technologies 44
2.4 TRANSMUCOSAL DRUG DELIVERY 44
2.4.1 Buccal Delivery 45
2.4.2 Nasal 47
2.4.3 Rectal 48
2.4.4 Vaginal 48
2.5 TRANSDERMAL DRUG DELIVERY 49
2.5.1 Passive Formulations 51
2.5.2 Active Formulations 52
2.6 NICHE TECHNOLOGIES 55
2.6.1 Topical Systems 56
2.6.2 Gene Delivery 58
2.6.3 Implantable Systems 60
2.6.4 Drug Delivery Microchips 63
2.6.5 Nanotechnology 66

3 OVERVIEW OF GLOBAL DRUG DELIVERY MARKET 70
3.1 IMPORTANCE OF DRUG DELIVERY 70
3.2 GLOBAL DRUG DELIVERY MARKET BY GEOGRAPHIC AREA 71
3.3 GLOBAL DRUG DELIVERY MARKET BY SEGMENT 72
3.4 GLOBAL DRUG DELIVERY MARKET FORECASTS 74

4 DRUG DELIVERY MARKET ANALYSIS 77
4.1 KEY MARKET SEGMENTS 77
4.1.1 Oral Drug Delivery 77
4.1.1.1 Sales of Products Utilizing Oral Drug Delivery Technology 77
4.1.1.2 Key Therapeutic Areas for Oral Drug Delivery 84
4.1.1.3 Key Oral Drug Delivery Products Impacting Global Market 86
4.1.1.4 The Outlook for Oral Drug Delivery Technology 92
4.1.1.5 Drivers and Restraints 93
4.1.2 Inhalable Drug Delivery 93
4.1.2.1 Sales of Products Utilizing Inhalable Drug Delivery Technology 93
4.1.2.2 Key Therapeutic Areas for Inhalable Drug Delivery 96
4.1.2.3 Key Inhalable Drug Delivery Products Impacting Global Market 97
4.1.2.4 The Outlook for Inhalable Drug Delivery Technology 104
4.1.2.5 Drivers and Restraints 105
4.1.3 Injectable Drug Delivery 106
4.1.3.1 Sales of Products Utilizing Injectable Drug Delivery Technology 106
4.1.3.2 Key Therapeutic Areas for Injectable Drug Delivery 110
4.1.3.3 Key Injectable Drug Delivery Products Impacting Global Market 113
4.1.3.4 The Outlook for Injectable Drug Delivery Technology 116
4.1.3.5 Drivers and Restraints 117
4.1.4 Transmucosal Drug Delivery 117
4.1.4.1 Sales of Products Utilizing Transmucosal Drug Delivery Technology 117
4.1.4.2 Key Therapeutic Areas for Transmucosal Delivery 120
4.1.4.3 Key Transmucosal Drug Delivery Products Impacting Global Market 121
4.1.4.4 The Outlook for Transmucosal Drug Delivery Technology 125
4.1.4.5 Drivers and Restraints 126
4.1.5 Transdermal Drug Delivery 127
4.1.5.1 Sales of Products Utilizing Transdermal Drug Delivery Technology 127
4.1.5.2 Key Therapeutic Areas for Transdermal Drug Delivery 131
4.1.5.3 Key Transdermal Drug Delivery Products Impacting Global Market 133
4.1.5.4 The Outlook for Transdermal Drug Delivery Technology 137
4.1.5.5 Drivers and Restraints 137
4.1.6 Niche Drug Delivery Technologies 138
4.1.6.1 Sales of Products Utilizing Niche Drug Delivery Technologies 138
4.1.6.2 Key Niche Drug Delivery Technology Product Impacting Global Market 141
4.1.6.3 The Outlook for Niche Drug Delivery Technologies 142
4.1.6.4 Drivers and Restraints 143

5 EMERGING DRUG DELIVERY TECHNOLOGIES: ORAL DRUG DELIVERY 144
5.1 KEY PRODUCT PROFILES 151
5.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF ORAL DRUG DELIVERY 156
5.2.1 ALZA 156
5.2.2 Biovail 157
5.2.3 Cardinal Health 161
5.2.4 Depomed 163
5.2.5 Emisphere 163
5.2.6 Ethypharm 164
5.2.7 Penwest 166

6 EMERGING DRUG DELIVERY TECHNOLOGIES: INHALABLE DRUG DELIVERY 167
6.1 KEY PRODUCT PROFILES 168
6.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF INHALABLE DRUG DELIVERY 171
6.2.1 3M 171
6.2.2 Alkermes 172
6.2.3 Aradigm 172
6.2.4 Nektar 173
6.2.5 SkyePharma 175

7 EMERGING DRUG DELIVERY TECHNOLOGIES: INJECTABLE DRUG DELIVERY 176
7.1 KEY PRODUCT PROFILES 179
7.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF INJECTABLE DRUG DELIVERY 182
7.2.1 Alkermes 182
7.2.2 ALZA 182
7.2.3 Enzon 183
7.2.4 Ethypharm 184
7.2.5 Macromed 185
7.2.6 Nektar 185
7.2.7 QLT 186

8 EMERGING DRUG DELIVERY TECHNOLOGIES: TRANSMUCOSAL DRUG DELIVERY 188
8.1 KEY PRODUCT PROFILES 190
8.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF TRANSMUCOSAL DRUG DELIVERY 193
8.2.1 Generex 193
8.2.2 Nastech 193
8.2.3 Pherin 194

9 EMERGING DRUG DELIVERY TECHNOLOGIES: TRANSDERMAL DRUG DELIVERY 197
9.1 KEY PRODUCT PROFILES 199
9.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF TRANSDERMAL DRUG DELIVERY 202
9.2.1 3M 202
9.2.2 Altea Therapeutics 203
9.2.3 ALZA 204
9.2.4 Aradigm 206
9.2.5 Noven 207

10 EMERGING DRUG DELIVERY TECHNOLOGIES: NICHE DRUG DELIVERY TECHNOLOGIES 209
10.1 KEY PRODUCT PROFILES 212
10.2 KEY COMPANY INVOLVEMENT IN NICHE DRUG DELIVERY TECHNOLOGIES 216
10.2.1 ALZA 216
10.2.2 Connetics (now Stiefel Laboratories) 216
10.2.3 Inovio 217
10.2.4 MacroChem 218
10.2.5 NexMed 218
10.2.6 pSivida 219
10.2.7 QLT 220
10.2.8 SkyePharma 221

11 KEY DRUG DELIVERY COMPANY PROFILES 224
11.1 3M PHARMACEUTICALS 224
11.2 ALKERMES 226
11.3 ALTEA THERAPEUTICS 227
11.4 ALZA (JOHNSON & JOHNSON) 229
11.5 ARADIGM 231
11.6 BIOJECT 232
11.7 BIOVAIL 234
11.8 CARDINAL HEALTH 236
11.9 CIMA LABS (CEPHALON) 237
11.10 CONNETICS (STIEFEL LABORATORIES INC.) 239
11.11 CYDEX PHARMACEUTICALS 241
11.12 DELSITE BIOTECHNOLOGIES (CARRINGTON LABORATORIES) 242
11.13 DEPOMED 243
11.14 DOR BIOPHARMA 245
11.15 DURECT 247
11.16 EMISPHERE 249
11.17 ENZON 251
11.18 ETHYPHARM 253
11.19 EURAND 255
11.20 GENEREX 256
11.21 INOVIO (FORMERLY GENETRONICS) 258
11.22 IVAX (PART OF TEVA) 261
11.23 MACROCHEM 262
11.24 MACROMED (NOW PROTHERICS) 263
11.25 NASTECH (NOW MDRNA) 265
11.26 NEKTAR 266
11.27 NEXMED 269
11.28 NOVEN 270
11.29 PSIVIDA 272
11.30 PENWEST 274
11.31 PHERIN PHARMACEUTICALS 276
11.32 QLT 277
11.33 SKYEPHARMA 279
11.34 WATSON PHARMACEUTICALS 281
11.35 ZOGENIX 283

Tables
TABLE 2.1 DRUGS SUITABLE OR UNSUITABLE FOR CONTROLLED RELEASE 30
TABLE 2.2 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DELIVERY 50
TABLE 3.1 GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY KEY SEGMENTS, 2007 72
TABLE 3.2 FORECAST GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY SEGMENT, US$ BILLION 75
TABLE 4.1 KEY ORAL DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN) 78
TABLE 4.2 LEADING ORAL DRUG DELIVERY COMPANIES 2007, KEY PRODUCTS AND SALES 2007 ($MN) 83
TABLE 4.3 KEY INHALABLE DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN) 94
TABLE 4.4 KEY INJECTABLE DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN) 106
TABLE 4.5 LEADING INJECTABLE DRUG DELIVERY COMPANIES 2007, KEY PRODUCTS AND SALES 2007 ($ MN) 109
TABLE 4.6 KEY TRANSMUCOSAL DRUG DELIVERY PRODUCTS, 2004-2007** 118
($ MN) 118
TABLE 4.7 KEY TRANSDERMAL DRUG DELIVERY PRODUCTS, 2004-2007# 128
($ MN) 128
TABLE 4.8 KEY TOPICAL DRUG DELIVERY PRODUCTS, 2007 138
TABLE 4.9 KEY NICHE DRUG DELIVERY PRODUCTS, 2004-2007 ($ MN) 140
TABLE 5.1 KEY ORAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008 144
TABLE 6.1 KEY INHALABLE DRUG DELIVERY R&D PIPELINE DRUGS, 2008 167
TABLE 7.1 KEY INJECTABLE DRUG DELIVERY R&D PIPELINE DRUGS, 2008 176
TABLE 8.1 KEY TRANSMUCOSAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008 188
TABLE 9.1 KEY TRANSDERMAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008 197
TABLE 10.1 KEY TOPICAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008 209
TABLE 10.2 KEY NICHE DRUG DELIVERY R&D PIPELINE DRUGS, 2008 210
TABLE 11.1 3M KEY FINANCIALS, 2003-2007 (US$MN) 224
TABLE 11.2 3M DRUG DELIVERY PORTFOLIO, 2008 225
TABLE 11.3 ALKERMES KEY FINANCIALS, 2003-2007 (US$MN) 226
TABLE 11.4 ALKERMES DRUG DELIVERY PORTFOLIO, 2008 227
TABLE 11.5 ALTEA THERAPEUTICS DRUG DELIVERY PORTFOLIO, 2008 228
TABLE 11.6 ALZA DRUG DELIVERY PORTFOLIO, 2008 229
TABLE 11.7 ARADIGM KEY FINANCIALS, 2003-2007 (US$MN) 231
TABLE 11.8 ARADIGM DRUG DELIVERY PORTFOLIO, 2008 232
TABLE 11.9 BIOJECT KEY FINANCIALS, 2003-2007 (US$MN) 233
TABLE 11.10 BIOJECT DRUG DELIVERY PORTFOLIO, 2008 233
TABLE 11.11 BIOVAIL KEY FINANCIALS, 2003-2007 (US$MN) 234
TABLE 11.12 BIOVAIL DRUG DELIVERY PORTFOLIO, 2008 235
TABLE 11.13 CARDINAL HEALTH KEY FINANCIALS, 2003-2007 (US$MN) 236
TABLE 11.14 CARDINAL HEALTH DRUG DELIVERY PORTFOLIO, 2008 237
TABLE 11.15 CEPHALON KEY FINANCIALS, 2003-2007 (US$MN) 238
TABLE 11.16 CIMA LABS DRUG DELIVERY PORTFOLIO, 2008 238
TABLE 11.17 CONNETICS KEY FINANCIALS, 2003-2007 (US$MN) 240
TABLE 11.18 CONNETICS DRUG DELIVERY PORTFOLIO, 2008 240
TABLE 11.19 CYDEX DRUG DELIVERY PIPELINE, 2008 242
TABLE 11.20 CARRINGTON LABORATORIES KEY FINANCIALS, 2003-2007 (US$MN) 243
TABLE 11.21 DEPOMED KEY FINANCIALS, 2003-2007 (US$MN) 244
TABLE 11.22 DEPOMED DRUG DELIVERY PORTFOLIO, 2008 245
TABLE 11.23 DOR BIOPHARMA KEY FINANCIALS, 2003-2007 (US$MN) 246
TABLE 11.24 DOR BIOPHARMA DRUG DELIVERY PORTFOLIO, 2008 246
TABLE 11.25 DURECT KEY FINANCIALS, 2003-2007 (US$MN) 247
TABLE 11.26 DURECT DRUG DELIVERY PORTFOLIO, 2008 248
TABLE 11.27 EMISPHERE KEY FINANCIALS, 2003-2007 (US$MN) 249
TABLE 11.28 EMISPHERE DRUG DELIVERY PORTFOLIO, 2008 250
TABLE 11.29 ENZON KEY FINANCIALS, 2003-2007 (US$MN) 251
TABLE 11.30 ENZON DRUG DELIVERY PORTFOLIO, 2008 252
TABLE 11.31 ETHYPHARM DRUG DELIVERY PORTFOLIO, 2008 253
TABLE 11.32 EURAND KEY FINANCIALS, 2003-2007 (US$MN) 255
TABLE 11.33 EURAND DRUG DELIVERY PORTFOLIO, 2008 256
TABLE 11.34 GENEREX KEY FINANCIALS, 2003-2007 (US$MN) 257
TABLE 11.35 GENEREX DRUG DELIVERY PORTFOLIO, 2008 257
TABLE 11.36 INOVIO KEY FINANCIALS, 2003-2007 (US$MN) 258
TABLE 11.37 INOVIO DRUG DELIVERY PORTFOLIO, 2008 259
TABLE 11.38 IVAX KEY FINANCIALS, 2003-2007 (US$MN) 261
TABLE 11.39 IVAX DRUG DELIVERY PORTFOLIO, 2008 262
TABLE 11.40 MACROCHEM KEY FINANCIALS, 2003-2007 (US$MN) 263
TABLE 11.41 MACROCHEM DRUG DELIVERY PORTFOLIO, 2008 263
TABLE 11.42 MACROMED DRUG DELIVERY PORTFOLIO, 2008 264
TABLE 11.43 NASTECH KEY FINANCIALS, 2003-2007 (US$MN) 265
TABLE 11.44 NASTECH DRUG DELIVERY PORTFOLIO, 2008 266
TABLE 11.45 NEKTAR KEY FINANCIALS, 2003-2007 (US$MN) 267
TABLE 11.46 NEKTAR DRUG DELIVERY PORTFOLIO, 2008 267
TABLE 11.47 NEXMED KEY FINANCIALS, 2003-2007 (US$MN) 269
TABLE 11.48 NEXMED DRUG DELIVERY PORTFOLIO, 2008 270
TABLE 11.49 NOVEN KEY FINANCIALS, 2003-2007 (US$MN) 271
TABLE 11.50 NOVEN DRUG DELIVERY PORTFOLIO, 2008 271
TABLE 11.51 PSIVIDA KEY FINANCIALS, 2003-2007 (US$MN) 273
TABLE 11.52 PSIVIDA DRUG DELIVERY PORTFOLIO, 2008 273
TABLE 11.53 PENWEST KEY FINANCIALS, 2003-2007 (US$MN) 274
TABLE 11.54 PENWEST DRUG DELIVERY PORTFOLIO, 2008 275
TABLE 11.55 PHERIN PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008 276
TABLE 11.56 QLT KEY FINANCIALS, 2003-2007 (US$MN) 277
TABLE 11.57 QLT DRUG DELIVERY PORTFOLIO, 2008 278
TABLE 11.58 SKYE PHARMA KEY FINANCIALS, 2003-2007 (US$MN) 279
TABLE 11.59 SKYEPHARMA DRUG DELIVERY PORTFOLIO, 2008 280
TABLE 11.60 WATSON KEY FINANCIALS, 2003-2007 (US$MN) 281
TABLE 11.61 WATSON PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008 282
TABLE 11.62 ZOGENIX PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008 283

Graphs
GRAPH 3.1 ESTIMATED DRUG DELIVERY MARKET BY MAIN GEOGRAPHIC REGIONS 71
GRAPH 3.2 GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY KEY SEGMENTS, 2007 73
GRAPH 3.3 FORECAST GLOBAL SALES OF DRUG DELIVERY MARKET BY SEGMENT, US$ BILLION 75
GRAPH 3.4 FORECAST 2007-2012 GROWTH OF GLOBAL DRUG DELIVERY MARKET BY SEGMENT 76
GRAPH 4.1 TOP 5 PRODUCTS UTILIZING ORAL DELIVERY, GLOBAL SALES 2007 ($ MN) 82
GRAPH 4.2 LEADING ORAL DRUG DELIVERY COMPANIES, COMBINED KEY PRODUCT VALUES 2007 ($ MN) 84
GRAPH 4.3 KEY THERAPEUTIC AREAS OF EMPHASIS FOR ORAL DRUG DELIVERY, # OF KEY MARKETED PRODUCTS, 2007 85
GRAPH 4.4 TOP 5 PRODUCTS UTILIZING INHALABLE DELIVERY, GLOBAL SALES 2007 ($ MN) 96
GRAPH 4.5 INHALABLE DRUG DELIVERY MARKET SHARE, BY TECHNOLOGY 2007 96
GRAPH 4.6 TOP 5 PRODUCTS UTILIZING INJECTABLE DELIVERY, GLOBAL SALES 2007 ($ MN) 108
GRAPH 4.7 LEADING INJECTABLE DRUG DELIVERY COMPANIES, COMBINED KEY PRODUCT VALUES 2007 ($ MN) 110
GRAPH 4.8 TOP 5 PRODUCTS UTILIZING TRANSMUCOSAL DELIVERY, GLOBAL SALES 2007 ($ MN) 119
GRAPH 4.9 LEADING DEVELOPERS OF TRANSMUCOSAL-BASED THERAPEUTICS 2007 ($ MN) 120
GRAPH 4.10 LEADING TRANSDERMAL DRUG DELIVERY COMPANIES, BY # OF PRODUCTS ON MARKET 130
GRAPH 4.11 KEY THERAPEUTIC AREAS OF EMPHASIS FOR TRANSDERMAL DRUG DELIVERY, # OF KEY MARKETED PRODUCTS 131
GRAPH 5.1 LEADING COMPANIES ACTIVE IN ORAL DRUG DELIVERY DEVELOPMENT 150
GRAPH 5.2 LEADING INDICATIONS FOR ORAL DRUG DELIVERY PRODUCTS IN DEVELOPMENT 151
GRAPH 6.1 LEADING COMPANIES ACTIVE IN INHALABLE DRUG DELIVERY DEVELOPMENT 168
GRAPH 7.1 LEADING COMPANIES ACTIVE IN INJECTABLE DRUG DELIVERY DEVELOPMENT 179
GRAPH 8.1 LEADING COMPANIES ACTIVE IN INJECTABLE DRUG DELIVERY DEVELOPMENT 189
GRAPH 9.1 LEADING COMPANIES ACTIVE IN TRANSDERMAL DRUG DELIVERY DEVELOPMENT 198
GRAPH 10.1 LEADING COMPANIES ACTIVE IN NICHE/TOPICAL DRUG DELIVERY DEVELOPMENT 211

Figures
FIGURE 1.1 OPTIMAL TIME FOR REFORMULATION 19
FIGURE 1.2 GROWTH PROSPECTS IN THE DRUG DELIVERY SECTOR 21
FIGURE 2.1 PULSATILE DRUG RELEASE 34

First Name
Last Name
Job Title
Company
Email Address

New Report Assesses Impact and Future of Drug Repositioning in the Pharma Industry - read more -

New Reports & Conferences eNewsletter

Table of Contents